PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18281123-9	2008	Treatment with SP600125 and transfection with DN-JNK blocked Bcl-xL phosphorylation, suggesting that JNK plays an important role in sulindac/ATO-induced Bcl-xL phosphorylation.	Sulindac	132-140	BCL2 like 1	Homo sapiens	61-67	
18281123-0	2008	A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation.	Sulindac	17-25	BCL2 like 1	Homo sapiens	154-160	
18281123-6	2008	Interestingly, a slower migrating Bcl-xL band was observed on immunoblots after treatment of cells with sulindac/ATO.	Sulindac	104-112	BCL2 like 1	Homo sapiens	34-40	
18281123-9	2008	Treatment with SP600125 and transfection with DN-JNK blocked Bcl-xL phosphorylation, suggesting that JNK plays an important role in sulindac/ATO-induced Bcl-xL phosphorylation.	Sulindac	132-140	BCL2 like 1	Homo sapiens	153-159	
18281123-10	2008	In conclusion, in H1299 human NSCLC cells, sulindac and ATO synergistically induce a high degree of apoptosis, which is mediated by the ROS-dependent JNK activation pathway via Bcl-xL phosphorylation.	Sulindac	43-51	BCL2 like 1	Homo sapiens	177-183	
14576498-13	2003	The expression of several cell cycle (p21, p27, cyclin D1) and apoptotic (survivin, Bcl-xL) regulatory proteins was altered after U0126 and/or sulindac treatment.	Sulindac	143-151	BCL2 like 1	Homo sapiens	84-90	
11912124-0	2002	Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).	Sulindac	91-99	BCL2 like 1	Homo sapiens	123-131